Advanced formulations for intranasal delivery of biologics

Rohrer, Julia; Lupo, Noemi; Bernkop‐Schnürch, Andreas

doi:10.1016/j.ijpharm.2018.10.029

Cited by 63 publications

(34 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The nose to brain delivery strategy, as a non-invasive technique, is a cost-efficient choice for the direct transport of drugs to the brain. The main advantages of IN administration are as follows: 1) non-invasive route; 2) absence of hepatic first-pass metabolism; 3) quick onset of action; 4) improvement of drug availability; and 5) convenient route, whereas the limitations are as follows: 1) histological toxicity; 2) nasal irritation; and 3) local side effects [ 91 ]. Nethertheless, clinical application of IN formulations remains a long way to develop.…”

Section: Discussionmentioning

confidence: 99%

Non-invasive intranasal administration route directly to the brain using dendrimer nanoplatforms: An opportunity to develop new CNS drugs

Mignani

Shi

Karpus

et al. 2021

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

There are several routes of administration to the brain, including intraparenchymal, intraventricular, and subarachnoid injections. The blood-brain barrier (BBB) impedes the permeation and access of most drugs to the central nervous system (CNS), and consequently, many neurological diseases remain undertreated. For past decades, to circumvent this effect, several nanocarriers have been developed to deliver drugs to the brain. Importantly, intranasal (IN) administration can allow direct delivery of drugs into the brain through the anatomical connection between the nasal cavity and brain without crossing the BBB. In this regard, dendrimers may possess great potential to deliver drugs to the brain by IN administration, bypassing the BBB and reducing systemic exposure and side effects, to treat diseases of the CNS. In this original concise review, we highlighted the few examples advocated regarding the use of dendrimers to deliver CNS drugs directly via IN. This review highlighed the few examples of the association of dendrimer encapsulating drugs ( e.g. , small compounds: haloperidol and paeonol; macromolecular compounds: dextran, insulin and calcitonin; and siRNA) using IN administration. Good efficiencies were observed. In addition, we will present the in vivo effects of PAMAM dendrimers after IN administration, globally, showing no general toxicity.

show abstract

Section: Discussionmentioning

confidence: 99%

Non-invasive intranasal administration route directly to the brain using dendrimer nanoplatforms: An opportunity to develop new CNS drugs

Mignani

Shi

Karpus

et al. 2021

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

show abstract

“…Because of the rapid clearance rate (12 to 15 min), drugs deposited in the nasal cavity could be easily removed by mucociliary clearance. With the use of mucoadhesive excipients, nasal retention time and drug absorption could be improved [ 61 ]. One of the unique features of intranasal delivery compared to other transmucosal routes is its capability to deliver drug molecules directly into the CNS.…”

Section: Intranasal Deliverymentioning

confidence: 99%

“…methylcellulose) and mucoadhesive polymers (e.g. polyacrylic acid and thiomers) are sometimes added in the formulation to reduce nasal drip and runoff [ 61 ]. However, the formulation should not be too viscous, otherwise it may hinder the atomisation process.…”

Section: Intranasal Deliverymentioning

confidence: 99%

Transmucosal drug administration as an alternative route in palliative and end-of-life care during the COVID-19 pandemic

Lam

Cheung

Chow

et al. 2020

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

The Coronavirus disease 2019 (COVID-19) pandemic has led to a surge in need for alternative routes of administration of drugs for end of life and palliative care, particularly in community settings. Transmucosal routes include intranasal, buccal, sublingual and rectal. They are non-invasive routes for systemic drug delivery with the possibility of self-administration, or administration by family caregivers. In addition, their ability to offer rapid onset of action with reduced first-pass metabolism make them suitable for use in palliative and end-of-life care to provide fast relief of symptoms. This is particularly important in COVID-19, as patients can deteriorate rapidly. Despite the advantages, these routes of administration face challenges including a relatively small surface area for effective drug absorption, small volume of fluid for drug dissolution and the presence of a mucus barrier, thereby limiting the number of drugs that are suitable to be delivered through the transmucosal route. In this review, the merits, challenges and limitations of each of these transmucosal routes are discussed. The goals are to provide insights into using transmucosal drug delivery to bring about the best possible symptom management for patients at the end of life, and to inspire scientists to develop new delivery systems to provide effective symptom management for this group of patients.

show abstract

“…Nasal drug administration is an increasingly interesting topic for research and development in the pharmaceutical field [ 4 , 90 ]. The nasal cavity has an area of approximately 150–200 cm 2 [ 91 ], is well-vascularized, and exhibits very good absorption [ 92 ], allowing multiple opportunities for the formulation of drug delivery systems to bypass the blood–brain barrier, such as gels [ 93 ], nanoparticles [ 94 ], microparticles [ 95 ], microspheres [ 96 , 97 ], emulsions [ 98 ], powders [ 99 , 100 ], lipid nanostructures [ 101 ], and inserts [ 102 ].…”

Section: The Nasal Routementioning

confidence: 99%

New Opportunity to Formulate Intranasal Vaccines and Drug Delivery Systems Based on Chitosan

Popescu

Ghica

Dinu-Pîrvu

et al. 2020

IJMS

View full text Add to dashboard Cite

In an attempt to develop drug delivery systems that bypass the blood–brain barrier (BBB) and prevent liver and intestinal degradation, it was concluded that nasal medication meets these criteria and can be used for drugs that have these drawbacks. The aim of this review is to present the influence of the properties of chitosan and its derivatives (mucoadhesion, permeability enhancement, surface tension, and zeta potential) on the development of suitable nasal drug delivery systems and on the nasal bioavailability of various active pharmaceutical ingredients. Interactions between chitosan and proteins, lipids, antigens, and other molecules lead to complexes that have their own applications or to changing characteristics of the substances involved in the bond (conformational changes, increased stability or solubility, etc.). Chitosan and its derivatives have their own actions (antibacterial, antifungal, immunostimulant, antioxidant, etc.) and can be used as such or in combination with other molecules from the same class to achieve a synergistic effect. The applicability of the properties is set out in the second part of the paper, where nasal formulations based on chitosan are described (vaccines, hydrogels, nanoparticles, nanostructured lipid carriers (NLC), powders, emulsions, etc.).

show abstract

Advanced formulations for intranasal delivery of biologics

Cited by 63 publications

References 114 publications

Non-invasive intranasal administration route directly to the brain using dendrimer nanoplatforms: An opportunity to develop new CNS drugs

Non-invasive intranasal administration route directly to the brain using dendrimer nanoplatforms: An opportunity to develop new CNS drugs

Transmucosal drug administration as an alternative route in palliative and end-of-life care during the COVID-19 pandemic

New Opportunity to Formulate Intranasal Vaccines and Drug Delivery Systems Based on Chitosan

Contact Info

Product

Resources

About